The DOI matches its Crossref record.
Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma
Abstract
Purpose: The primary objective was to assess the duration of grade 4 neutropenia (neutrophil count < 0.5 × 10 9/L) after one cycle of chemotherapy with etoposide, methylprednisolone, cisplatin, and cytarabine in patients randomly assigned to receive one dose of pegfilgrastim or daily filgrastim after chemotherapy. Febrile neutropenia, neutrophil profiles, time to neutrophil recovery, pharmacokinetics, and safety were also assessed. Patients and Methods: An open-label, randomized, phase II study was designed to compare the effects of a single subcutaneous injection of pegfilgrastim (sustained-duration filgrastim) 100 μg/kg per chemotherapy cycle (n = 33) with daily subcutaneous injections of filgrastim 5 μg/kg (n = 33) in patients receiving salvage chemotherapy for relapsed or refractory Hodgkin’s or non-Hodgkin’s lymphoma. Results: The incidence of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 69% and 68%, respectively. In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively). The results for the two groups were also not significantly different for febrile neutropenia, neutrophil profile, time to neutrophil recovery, or toxicity profile. A single subcutaneous injection of pegfilgrastim 100 μg/kg produced a sustained serum concentration relative to daily subcutaneous injections of filgrastim. Filgrastim-treated patients received a median of 11 injections per cycle. Conclusion: Pegfilgrastim was safe and well tolerated in this patient population. A single injection of pegfilgrastim per chemotherapy cycle provided neutrophil support with safety and efficacy similar to that provided by daily injections of filgrastim. Once-per-cycle administration of pegfilgrastim simplifies the management of neutropenia and may have important clinical benefits for patients and healthcare providers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Aapro, M. S., Cameron, D. A., Pettengell, R., Bohlius, J., Crawford, J., Ellis, M., Kearney, N., Lyman, G. H., Tjan-Heijnen, V. C., Walewski, J., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.002 · Cited by 539
Filgrastim improves survival in lethally irradiated nonhuman primates
Farese, A. M., Cohen, M. V., Katz, B. P., Smith, C. P., Gibbs, A., Cohen, D. M., & MacVittie, T. J. (2013) · Radiation Research · doi:10.1667/rr3049.1 · Cited by 187
Pegfilgrastim improves survival of lethally irradiated nonhuman primates
Hankey, K. G., Farese, A. M., Blaauw, E. C., Gibbs, A. M., Smith, C. P., Katz, B. P., Tong, Y., Prado, K. L., & MacVittie, T. J. (2015) · Radiation Research · doi:10.1667/rr13940.1 · Cited by 129
Metadata
- Authors
- Vose, J. M., Crump, M., Lazarus, H., Emmanouilides, C., Schenkein, D., Moore, J., Frankel, S., Flinn, I., Lovelace, W., Hackett, J., & Liang, B. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-02-01
- Volume
- 21
- Issue
- 3
- Pages
- 514-519
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106833866
- Cited by
- 187
- References
- 0
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2003.03.040
- The paper
- Vose, J. M., Crump, M., Lazarus, H., Emmanouilides, C., Schenkein, D., Moore, J., Frankel, S., Flinn, I., Lovelace, W., Hackett, J., & Liang, B. C. (2003). Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.03.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.